Daily oral supplementation with açai berry lessened motor and nonmotor deficits in a mouse model of Parkinson’s disease, a study showed. These benefits were accompanied by a reduction in neuroinflammation, alpha-synuclein protein accumulation, a type of cellular damage called oxidative stress, and dopaminergic neuron loss — all implicated in…
A new psychedelic drug formulation called AKO004 is now under development by Akome Biotech, a wholly owned subsidiary of Core One Labs, as a potential treatment for Parkinson’s disease. The company has filed a provisional patent application for AKO004 with the U.S. Patent and Trademark Office. The AKO004…
In the presence of mitochondrial dysfunction, nerve cells (neurons) switch to an alternative metabolic program to resist neurodegeneration, according to a recent study in mice. Interestingly, the data suggested that such a metabolic program is not a one-way road to neurodegeneration, but rather a compensatory mechanism that can be reversed…
Deregulation of calcium levels in nerve cells has been linked to early symptoms of Parkinson’s disease. Now, researchers at Aarhus University have found that inhibition of a protein called SERCA can prevent calcium variations and protect nerve cells from degeneration. This finding may open new therapeutic avenues to treat…
Get regular updates to your inbox.
